Correction to: A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma (International Journal of Hematology, (2019), 109, 1, (107-114), 10.1007/s12185-018-2543-y)

on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)

Research output: Contribution to journalComment/debate

Abstract

In the original publication of this article, “Conflict of interest” was published incorrectly. The corrected “Conflict of interest” is given below for your reading. Conflict of interest Dr. Sunami reports grants from GlaxoSmithKline, Novartis, Janssen, Sanofi, MSD, Alexion Pharma, Daiichi-Sankyo, and Abbvie, and grants and personal fees from Ono pharmaceutical, Takeda pharmaceutical, Celgene, and Bristol-Myers Squibb. Dr. Matsumoto reports personal fees from Celgene, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, and Takeda Pharmaceutical. Dr. Okumura reports personal fees from Celgene. Dr. Murayama reports personal fees from Bristol-Myers Squibb, Celgene, Eisai, Janssen, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mundipharma, Beckman Coulter, and Chugai Pharmaceutical. Dr. Miyamoto reports personal fees from Celgene. Dr. Shimazaki reports personal fees from Ono Pharmaceutical, Celgene, and Fujimoto Pharmaceutical. Dr. Akashi reports personal fees from Celgene and Janssen, grants from Nippon Kayaku, and grants and personal fees from Kyowa Hakko Kirin, Takeda Pharmaceutical, Shionogi, and Mochida Pharmaceutical. Dr. Harada reports personal fees from Celgene.

Original languageEnglish
Number of pages1
JournalInternational journal of hematology
Volume109
Issue number1
DOIs
Publication statusPublished - Jan 22 2019

Fingerprint

Hematology
Multiple Myeloma
Fees and Charges
Pharmaceutical Preparations
Organized Financing
Pharmaceutical Fees
Conflict of Interest
Therapeutics
lenalidomide
Publications
Reading
Delivery of Health Care

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{b03f0a57fdc74eb794baa270d4684f36,
title = "Correction to: A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma (International Journal of Hematology, (2019), 109, 1, (107-114), 10.1007/s12185-018-2543-y)",
abstract = "In the original publication of this article, “Conflict of interest” was published incorrectly. The corrected “Conflict of interest” is given below for your reading. Conflict of interest Dr. Sunami reports grants from GlaxoSmithKline, Novartis, Janssen, Sanofi, MSD, Alexion Pharma, Daiichi-Sankyo, and Abbvie, and grants and personal fees from Ono pharmaceutical, Takeda pharmaceutical, Celgene, and Bristol-Myers Squibb. Dr. Matsumoto reports personal fees from Celgene, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, and Takeda Pharmaceutical. Dr. Okumura reports personal fees from Celgene. Dr. Murayama reports personal fees from Bristol-Myers Squibb, Celgene, Eisai, Janssen, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mundipharma, Beckman Coulter, and Chugai Pharmaceutical. Dr. Miyamoto reports personal fees from Celgene. Dr. Shimazaki reports personal fees from Ono Pharmaceutical, Celgene, and Fujimoto Pharmaceutical. Dr. Akashi reports personal fees from Celgene and Janssen, grants from Nippon Kayaku, and grants and personal fees from Kyowa Hakko Kirin, Takeda Pharmaceutical, Shionogi, and Mochida Pharmaceutical. Dr. Harada reports personal fees from Celgene.",
author = "{on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)} and Fuchida, {Shin ichi} and Kazutaka Sunami and Morio Matsumoto and Hirokazu Okumura and Tohru Murayama and Toshihiro Miyamoto and Eichi Otsuka and Naohito Fujishima and Tohru Izumi and Shigehisa Tamaki and Yasushi Hiramatsu and Yoshiaki Kuroda and Chihiro Shimazaki and Koichi Akashi and Mine Harada",
year = "2019",
month = "1",
day = "22",
doi = "10.1007/s12185-018-2557-5",
language = "English",
volume = "109",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Correction to

T2 - A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma (International Journal of Hematology, (2019), 109, 1, (107-114), 10.1007/s12185-018-2543-y)

AU - on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)

AU - Fuchida, Shin ichi

AU - Sunami, Kazutaka

AU - Matsumoto, Morio

AU - Okumura, Hirokazu

AU - Murayama, Tohru

AU - Miyamoto, Toshihiro

AU - Otsuka, Eichi

AU - Fujishima, Naohito

AU - Izumi, Tohru

AU - Tamaki, Shigehisa

AU - Hiramatsu, Yasushi

AU - Kuroda, Yoshiaki

AU - Shimazaki, Chihiro

AU - Akashi, Koichi

AU - Harada, Mine

PY - 2019/1/22

Y1 - 2019/1/22

N2 - In the original publication of this article, “Conflict of interest” was published incorrectly. The corrected “Conflict of interest” is given below for your reading. Conflict of interest Dr. Sunami reports grants from GlaxoSmithKline, Novartis, Janssen, Sanofi, MSD, Alexion Pharma, Daiichi-Sankyo, and Abbvie, and grants and personal fees from Ono pharmaceutical, Takeda pharmaceutical, Celgene, and Bristol-Myers Squibb. Dr. Matsumoto reports personal fees from Celgene, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, and Takeda Pharmaceutical. Dr. Okumura reports personal fees from Celgene. Dr. Murayama reports personal fees from Bristol-Myers Squibb, Celgene, Eisai, Janssen, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mundipharma, Beckman Coulter, and Chugai Pharmaceutical. Dr. Miyamoto reports personal fees from Celgene. Dr. Shimazaki reports personal fees from Ono Pharmaceutical, Celgene, and Fujimoto Pharmaceutical. Dr. Akashi reports personal fees from Celgene and Janssen, grants from Nippon Kayaku, and grants and personal fees from Kyowa Hakko Kirin, Takeda Pharmaceutical, Shionogi, and Mochida Pharmaceutical. Dr. Harada reports personal fees from Celgene.

AB - In the original publication of this article, “Conflict of interest” was published incorrectly. The corrected “Conflict of interest” is given below for your reading. Conflict of interest Dr. Sunami reports grants from GlaxoSmithKline, Novartis, Janssen, Sanofi, MSD, Alexion Pharma, Daiichi-Sankyo, and Abbvie, and grants and personal fees from Ono pharmaceutical, Takeda pharmaceutical, Celgene, and Bristol-Myers Squibb. Dr. Matsumoto reports personal fees from Celgene, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, and Takeda Pharmaceutical. Dr. Okumura reports personal fees from Celgene. Dr. Murayama reports personal fees from Bristol-Myers Squibb, Celgene, Eisai, Janssen, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mundipharma, Beckman Coulter, and Chugai Pharmaceutical. Dr. Miyamoto reports personal fees from Celgene. Dr. Shimazaki reports personal fees from Ono Pharmaceutical, Celgene, and Fujimoto Pharmaceutical. Dr. Akashi reports personal fees from Celgene and Janssen, grants from Nippon Kayaku, and grants and personal fees from Kyowa Hakko Kirin, Takeda Pharmaceutical, Shionogi, and Mochida Pharmaceutical. Dr. Harada reports personal fees from Celgene.

UR - http://www.scopus.com/inward/record.url?scp=85056133834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056133834&partnerID=8YFLogxK

U2 - 10.1007/s12185-018-2557-5

DO - 10.1007/s12185-018-2557-5

M3 - Comment/debate

C2 - 30406327

AN - SCOPUS:85056133834

VL - 109

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -